• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吸入炭疽孢子攻击未治疗或左氧氟沙星/raxibacumab 治疗的新西兰白兔中的炭疽杆菌保护性抗原动力学。

Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.

机构信息

Human Genome Sciences, Inc., 14200 Shady Grove Road, Rockville, MD 20850, USA.

出版信息

Toxins (Basel). 2013 Jan 14;5(1):120-38. doi: 10.3390/toxins5010120.

DOI:10.3390/toxins5010120
PMID:23344456
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3564073/
Abstract

Inhaled Bacillus anthracis spores germinate and the subsequent vegetative growth results in bacteremia and toxin production. Anthrax toxin is tripartite: the lethal factor and edema factor are enzymatic moieties, while the protective antigen (PA) binds to cell receptors and the enzymatic moieties. Antibiotics can control B. anthracis bacteremia, whereas raxibacumab binds PA and blocks lethal toxin effects. This study assessed plasma PA kinetics in rabbits following an inhaled B. anthracis spore challenge. Additionally, at 84 h post-challenge, 42% of challenged rabbits that had survived were treated with either levofloxacin/placebo or levofloxacin/raxibacumab. The profiles were modeled using a modified Gompertz/second exponential growth phase model in untreated rabbits, with added monoexponential PA elimination in treated rabbits. Shorter survival times were related to a higher plateau and a faster increase in PA levels. PA elimination half-lives were 10 and 19 h for the levofloxacin/placebo and levofloxacin/raxibacumab groups, respectively, with the difference attributable to persistent circulating PA-raxibacumab complex. PA kinetics were similar between untreated and treated rabbits, with one exception: treated rabbits had a plateau phase nearly twice as long as that for untreated rabbits. Treated rabbits that succumbed to disease had higher plateau PA levels and shorter plateau duration than surviving treated rabbits.

摘要

吸入炭疽芽孢后,芽孢发芽,随后的营养生长导致菌血症和毒素产生。炭疽毒素为三聚体:致死因子和水肿因子为酶部分,而保护性抗原(PA)与细胞受体结合,并与酶部分结合。抗生素可以控制炭疽杆菌菌血症,而 raxibacumab 结合 PA 并阻断致死毒素的作用。本研究评估了吸入炭疽芽孢后家兔的血浆 PA 动力学。此外,在挑战后 84 小时,42%幸存的受挑战兔子接受左氧氟沙星/安慰剂或左氧氟沙星/raxibacumab 治疗。在未治疗的兔子中,使用改良的 Gompertz/二次指数生长阶段模型对曲线进行建模,在治疗的兔子中加入单指数 PA 消除。较短的存活时间与较高的平台期和 PA 水平的快速增加有关。左氧氟沙星/安慰剂和左氧氟沙星/raxibacumab 组的 PA 消除半衰期分别为 10 和 19 小时,差异归因于持续循环的 PA-raxibacumab 复合物。未经治疗和治疗的兔子之间的 PA 动力学相似,只有一个例外:治疗的兔子的平台期几乎是未经治疗的兔子的两倍长。患病而死亡的治疗兔子的平台期 PA 水平较高,平台期持续时间较短。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/e7b0682e7275/toxins-05-00120-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/2755c602c0df/toxins-05-00120-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/b1b462eadd49/toxins-05-00120-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/1eefcbc50c5d/toxins-05-00120-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/dd21ef990849/toxins-05-00120-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/e7b0682e7275/toxins-05-00120-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/2755c602c0df/toxins-05-00120-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/b1b462eadd49/toxins-05-00120-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/1eefcbc50c5d/toxins-05-00120-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/dd21ef990849/toxins-05-00120-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e02/3564073/e7b0682e7275/toxins-05-00120-g005.jpg

相似文献

1
Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.吸入炭疽孢子攻击未治疗或左氧氟沙星/raxibacumab 治疗的新西兰白兔中的炭疽杆菌保护性抗原动力学。
Toxins (Basel). 2013 Jan 14;5(1):120-38. doi: 10.3390/toxins5010120.
2
Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen.新西兰白兔在接受炭疽芽孢杆菌孢子挑战并使用抗生素和抗保护性抗原单克隆抗体奥立妥昔单抗治疗后保护性免疫的发展。
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01590-17. Print 2018 Feb.
3
An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.一种同时针对炭疽杆菌毒素和细菌的鼻内疫苗可使兔子抵御气溶胶孢子攻击。
Vaccine. 2006 May 1;24(18):3953-63. doi: 10.1016/j.vaccine.2006.02.024. Epub 2006 Feb 28.
4
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.在新西兰白兔吸入性炭疽模型中,重组保护性抗原炭疽疫苗与抗生素联合作为暴露后预防措施使用时可提高生存率。
Clin Vaccine Immunol. 2012 Aug;19(8):1158-64. doi: 10.1128/CVI.00240-12. Epub 2012 Jun 13.
5
Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection.用重组的、荧光假单胞菌表达的炭疽芽孢杆菌衍生保护性抗原突变体对兔子进行免疫可使其免受炭疽感染。
PLoS One. 2015 Jul 24;10(7):e0130952. doi: 10.1371/journal.pone.0130952. eCollection 2015.
6
The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.抗炭疽芽孢杆菌抗体和炭疽毒素成分在抑制炭疽芽孢感染早期阶段中的作用。
Microbiology (Reading). 2001 Jun;147(Pt 6):1677-1685. doi: 10.1099/00221287-147-6-1677.
7
Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.炭疽疫苗抗原-佐剂配方能完全保护新西兰白兔免受炭疽杆菌埃姆斯菌株孢子的攻击。
Clin Vaccine Immunol. 2012 Jan;19(1):11-6. doi: 10.1128/CVI.05376-11. Epub 2011 Nov 16.
8
A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge.一种针对炭疽保护性抗原的高亲和力单克隆抗体,在雾化炭疽芽孢杆菌孢子攻击前后均能被动保护兔子。
Infect Immun. 2005 Feb;73(2):795-802. doi: 10.1128/IAI.73.2.795-802.2005.
9
Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model.针对保护性抗原的人源单克隆抗体AVP-21D9可减少炭疽芽孢杆菌埃姆斯菌株在兔模型中从肺部的播散。
Infect Immun. 2007 Jul;75(7):3414-24. doi: 10.1128/IAI.00352-07. Epub 2007 Apr 23.
10
A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.一种阳离子脂质体配方的质粒DNA疫苗可提供针对雾化炭疽芽孢的持续抗体介导保护。
Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13601-6. doi: 10.1073/pnas.0405557101. Epub 2004 Sep 1.

引用本文的文献

1
Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax.治疗用 gepotidacin 在吸入性炭疽病兔模型中的疗效。
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0149723. doi: 10.1128/aac.01497-23. Epub 2024 Feb 15.
2
Recent Advances in Monoclonal Antibody-Based Approaches in the Management of Bacterial Sepsis.基于单克隆抗体的细菌脓毒症治疗方法的最新进展
Biomedicines. 2023 Mar 2;11(3):765. doi: 10.3390/biomedicines11030765.
3
Efficacy of ANTHRASIL (Anthrax Immune Globulin Intravenous (Human)) in rabbit and nonhuman primate models of inhalational anthrax: Data supporting approval under animal rule.

本文引用的文献

1
Raxibacumab for the treatment of inhalational anthrax.瑞西巴库单抗用于治疗吸入性炭疽。
N Engl J Med. 2009 Jul 9;361(2):135-44. doi: 10.1056/NEJMoa0810603.
2
Animal studies in the development of medical countermeasures.医学应对措施研发中的动物研究。
Clin Pharmacol Ther. 2008 Jun;83(6):918-20. doi: 10.1038/clpt.2008.23. Epub 2008 Mar 5.
3
Pathology of inhalational anthrax infection in the african green monkey.非洲绿猴吸入性炭疽感染的病理学
炭疽免疫球蛋白静脉注射(人用)(ANTHRASIL)在兔和非人类灵长类动物吸入性炭疽模型中的疗效:支持根据动物规则批准的数据。
PLoS One. 2023 Mar 17;18(3):e0283164. doi: 10.1371/journal.pone.0283164. eCollection 2023.
4
Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives.外毒素靶向药物模式作为抗生素替代品。
ACS Infect Dis. 2022 Mar 11;8(3):433-456. doi: 10.1021/acsinfecdis.1c00296. Epub 2022 Jan 31.
5
Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax.评价脂质体环丙沙星制剂在炭疽病小鼠模型中的应用。
PLoS One. 2020 Jan 24;15(1):e0228162. doi: 10.1371/journal.pone.0228162. eCollection 2020.
6
Pharmacokinetic and Pharmacodynamic Considerations for the Use of Monoclonal Antibodies in the Treatment of Bacterial Infections.单克隆抗体用于治疗细菌感染的药代动力学和药效学考量
Antibodies (Basel). 2018 Jan 4;7(1):5. doi: 10.3390/antib7010005.
7
Accurate and selective quantification of anthrax protective antigen in plasma by immunocapture and isotope dilution mass spectrometry.通过免疫捕获和同位素稀释质谱法准确、选择性地定量血浆中的炭疽保护性抗原。
Analyst. 2019 Mar 25;144(7):2264-2274. doi: 10.1039/c8an02479k.
8
Establishment of a New Zealand White Rabbit Model for Lethal Toxin (LT) Challenge and Efficacy of Monoclonal Antibody 5E11 in the LT-Challenged Rabbit Model.新西兰白兔致死毒素(LT)攻毒模型的建立及单克隆抗体 5E11 在 LT 攻毒兔模型中的疗效。
Toxins (Basel). 2018 Jul 12;10(7):289. doi: 10.3390/toxins10070289.
9
Passive protection against anthrax in mice with plasma derived from horses hyper-immunized against Sterne strain.用针对斯特恩菌株进行过超免疫的马所产生的血浆对小鼠进行炭疽被动保护。
PeerJ. 2017 Dec 15;5:e3907. doi: 10.7717/peerj.3907. eCollection 2017.
10
Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy.包括抗毒素治疗在内的有效人类吸入性炭疽治疗的时间周期估计。
PLoS Curr. 2017 Jul 28;9:ecurrents.outbreaks.7896c43f69838f17ce1c2c372e79d55d. doi: 10.1371/currents.outbreaks.7896c43f69838f17ce1c2c372e79d55d.
Vet Pathol. 2007 Sep;44(5):716-21. doi: 10.1354/vp.44-5-716.
4
Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model.左氧氟沙星在吸入性炭疽(暴露后)恒河猴模型中的药代动力学考量及疗效
Antimicrob Agents Chemother. 2006 Nov;50(11):3535-42. doi: 10.1128/AAC.00090-06.
5
Protective antigen as a correlative marker for anthrax in animal models.保护性抗原作为动物模型中炭疽的相关标志物。
Infect Immun. 2006 Oct;74(10):5871-6. doi: 10.1128/IAI.00792-06.
6
The Gompertz Curve as a Growth Curve.作为生长曲线的冈珀茨曲线
Proc Natl Acad Sci U S A. 1932 Jan;18(1):1-8. doi: 10.1073/pnas.18.1.1.
7
Systematic review: a century of inhalational anthrax cases from 1900 to 2005.系统评价:1900年至2005年的一个世纪吸入性炭疽病例
Ann Intern Med. 2006 Feb 21;144(4):270-80. doi: 10.7326/0003-4819-144-4-200602210-00009.
8
Modeling of the bacterial growth curve.细菌生长曲线的建模。
Appl Environ Microbiol. 1990 Jun;56(6):1875-81. doi: 10.1128/aem.56.6.1875-1881.1990.
9
A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers.在健康志愿者中开展的一项关于PAmAb(一种抗炭疽杆菌保护性抗原的全人单克隆抗体)的1期研究。
Clin Infect Dis. 2005 Jul 1;41(1):12-20. doi: 10.1086/430708. Epub 2005 May 24.
10
Production and purification of Bacillus anthracis protective antigen from Escherichia coli.从大肠杆菌中生产和纯化炭疽芽孢杆菌保护性抗原
Protein Expr Purif. 2004 Nov;38(1):145-52. doi: 10.1016/j.pep.2004.08.007.